About the Uterus Volume Calculator
This calculator estimates uterine volume using the prolate ellipsoid formula: Volume = Length × Width × Height × 0.523. This method is standard in gynecologic ultrasound and provides a reproducible estimate of uterine size for clinical and research purposes. The formula models the uterus as a prolate spheroid, applying the constant π/6 (0.5236) to the product of the three principal uterine diameters.
Uterine volume is one of the most practically important measurements in gynecologic imaging. The uterus undergoes significant volume changes across a woman's lifetime — from the small prepubertal uterus (less than 2 mL) through the reproductive years (where size is influenced by parity and hormonal environment) to the postmenopausal atrophic uterus. Abnormal uterine volume — both enlarged and, less commonly, abnormally small — provides critical diagnostic information for a wide range of conditions affecting women at all reproductive ages.
The most clinically significant causes of uterine enlargement are uterine fibroids (leiomyomas) and adenomyosis, which together account for the majority of abnormal uterine bleeding in premenopausal women. Accurate volume measurement is essential for treatment planning, monitoring medical or procedural therapy response, and determining surgical candidacy. In clinical trials of fibroid therapies, total uterine volume reduction is a co-primary or secondary endpoint endorsed by regulatory agencies including the FDA.
How to Use This Calculator
Obtain three orthogonal uterine measurements from transvaginal or transabdominal ultrasound. Select the patient's menopausal status and parity, enter the three dimensions in centimeters, then press "Calculate Volume." Results are compared against parity- and menopausal-status-appropriate reference ranges.
Length — the longitudinal diameter measured from the uterine fundus to the external cervical os in the sagittal plane. This is the most reproducible single measurement of uterine size. Note: some institutions measure the uterine corpus only (fundus to internal os) rather than the total uterine length — specify which method is used when recording measurements.
Width — the maximum transverse diameter measured in the coronal or axial plane at the widest point, typically at the uterine fundus.
Height (AP diameter) — the anteroposterior diameter measured in the sagittal plane, perpendicular to the length. This represents the "thickness" of the uterus from anterior to posterior wall.
Transvaginal ultrasound provides superior resolution for measurement of the uterine corpus and endometrium. Transabdominal scanning is required for very large uteri that extend beyond the pelvis, or when the transvaginal approach is not feasible. MRI provides the most accurate three-dimensional uterine volume measurement and is preferred when fibroid mapping is required for surgical planning.
Interpretation Guide
| Category | Normal Range | Upper Limit |
|---|---|---|
| Premenopausal, nulliparous | 20 – 70 mL | 70 mL |
| Premenopausal, parous | 20 – 90 mL | 90 mL |
| Postmenopausal | < 20 mL | 20 mL |
Normal uterine volume in nulliparous premenopausal women is generally 20–70 mL, with parous women having somewhat larger uteri due to the permanent hypertrophic changes of prior pregnancy. Volumes above the upper limit of normal for the patient's category should prompt investigation for fibroids, adenomyosis, or other pathology. A significantly enlarged uterus (volume >200 mL) almost always reflects fibroid disease or adenomyosis, and a uterus >500 mL is equivalent to approximately 12–14 weeks gestational size.
In postmenopausal women, uterine volume should be less than 20 mL. Any enlargement above this threshold warrants evaluation of the endometrial stripe thickness and, if thickened or irregular, endometrial sampling. Postmenopausal uterine enlargement in the absence of exogenous hormone therapy or HRT raises concern for endometrial pathology including polyps, hyperplasia, or carcinoma.
Clinical Significance
Uterine volume assessment is used to diagnose and monitor uterine fibroids (leiomyomata), adenomyosis, and uterine anomalies. A significantly enlarged uterus (volume > 200 mL) typically warrants further workup. Postmenopausal uterine enlargement (> 20 mL) should prompt evaluation for endometrial pathology. Uterine volume also plays a role in evaluating uterine factor infertility and Mullerian anomalies, where an unusually small uterus may indicate hypoplasia or an infantile uterus.
Fibroids and Uterine Volume
Uterine fibroids are the most common cause of uterine enlargement in premenopausal women, affecting up to 70% of women by age 50. Volume measurements are used to track response to medical therapy (e.g., GnRH agonists, relugolix) or uterine artery embolization. A 20–30% volume reduction is typically considered a meaningful clinical response. The FIGO (International Federation of Gynecology and Obstetrics) fibroid classification system (0–8) describes fibroid location relative to the uterine layers, which influences symptom pattern and treatment selection. Intramural and submucosal fibroids contribute most to abnormal uterine bleeding and infertility.
Adenomyosis and Uterine Volume
Adenomyosis — endometrial glands and stroma within the myometrium — causes diffuse uterine enlargement with a globular uterine shape and heterogeneous myometrial echotexture on ultrasound. Classic ultrasound features include asymmetric myometrial thickening, subendometrial echogenic nodules, myometrial cysts ("Swiss cheese" pattern), and poor definition of the endometrial-myometrial junction. Uterine volume in severe adenomyosis may exceed 200–300 mL. MRI is the most sensitive and specific imaging modality for adenomyosis diagnosis, showing thickening of the junctional zone (>12 mm) on T2-weighted sequences.
Measurement Technique
Measure the uterus in three orthogonal planes. The longitudinal (length) measurement runs from the fundus to the external cervical os. The transverse and AP diameters are obtained in the axial/coronal and sagittal planes, respectively. Include the cervix if instructed; most uterine volume studies measure the corpus only. For very large, irregularly shaped uteri with multiple fibroids, the ellipsoid formula will underestimate the true volume, and dedicated 3D ultrasound or MRI volumetry is preferred.
Limitations & Considerations
The ellipsoid formula assumes a regular, symmetric uterine shape. In patients with multiple fibroids, significant uterine asymmetry, or bicornuate/arcuate uterine anomalies, the formula is less accurate. For a fibroid uterus with multiple large masses distorting the contour, 3D ultrasound volumetry or MRI is more accurate than the simple ellipsoid calculation.
Measurement reproducibility is a key challenge for uterine volume. The cervix-to-fundus length is subject to variability depending on bladder filling (a full bladder elongates the apparent uterine length on transabdominal scanning), uterine position (retroflexed uteri may appear foreshortened in the sagittal plane on transabdominal scanning), and the challenge of consistently identifying the external cervical os versus internal os as the inferior landmark.
The normal ranges provided are derived from published population studies but considerable inter-individual variation exists. Parity is the most important modifier of normal uterine volume in premenopausal women — a woman who has had five pregnancies may have a larger uterus at baseline than a nulliparous woman even in the absence of pathology. Clinical symptoms (menorrhagia, pelvic pain, pressure symptoms, urinary frequency) are as important as absolute volume when determining whether a borderline-enlarged uterus requires treatment.
References
Munro MG, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding. Int J Gynecol Obstet. 2011;113(1):3-13.
Naftalin J, et al. Prevalence, distribution and 3-dimensional anatomy of adenomyosis. Ultrasound Obstet Gynecol. 2012;39(6):709-712.
Dueholm M, et al. Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis. Fertil Steril. 2001;76(3):588-594.
Laughlin-Tommaso SK, et al. Uterine fibroids: impact on quality of life and treatment options. Obstet Gynecol Clin North Am. 2019;46(3):413-427.